This is an archive of papers published by the staff and faculty of Fox Chase Cancer Center. For questions about content, please contact Talbot Research Library
Last updated on
Morel KL , Sheahan AV , Burkhart DL , Baca SC , Boufaied N , Liu Y , Qiu X , Cañadas I , Roehle K , Heckler M , Calagua C , Ye H , Pantelidou C , Galbo P , Panja S , Mitrofanova A , Wilkinson S , Whitlock NC , Trostel SY , Hamid AA , Kibel AS , Barbie DA , Choudhury AD , Pomerantz MM , Sweeney CJ , Long HW , Einstein DJ , Shapiro GI , Dougan SK , Sowalsky AG , He HH , Freedman ML , Balk SP , Loda M , Labbé DP , Olson BM , Ellis L
EZH2 inhibition activates a dsRNA-STING-interferon stress axis that potentiates response to PD-1 checkpoint blockade in prostate cancer
Nat Cancer. 2021 Apr;2(4) :444-456
PMID: 33899001 PMCID: PMC8061902
AbstractProstate cancers are considered to be immunologically 'cold' tumors given the very few patients who respond to checkpoint inhibitor (CPI) therapy. Recently, enrichment of interferon-stimulated genes (ISGs) predicted a favorable response to CPI across various disease sites. The enhancer of zeste homolog-2 (EZH2) is overexpressed in prostate cancer and known to negatively regulate ISGs. In the present study, we demonstrate that EZH2 inhibition in prostate cancer models activates a double-stranded RNA-STING-ISG stress response upregulating genes involved in antigen presentation, Th1 chemokine signaling and interferon response, including programmed cell death protein 1 (PD-L1) that is dependent on STING activation. EZH2 inhibition substantially increased intratumoral trafficking of activated CD8(+) T cells and increased M1 tumor-associated macrophages, overall reversing resistance to PD-1 CPI. Our study identifies EZH2 as a potent inhibitor of antitumor immunity and responsiveness to CPI. These data suggest EZH2 inhibition as a therapeutic direction to enhance prostate cancer response to PD-1 CPI.
Notes2662-1347 Morel, Katherine L Orcid: 0000-0002-7968-4032 Sheahan, Anjali V Burkhart, Deborah L Baca, Sylvan C Boufaied, Nadia Liu, Yin Qiu, Xintao Orcid: 0000-0002-8560-7017 Cañadas, Israel Roehle, Kevin Heckler, Max Calagua, Carla Ye, Huihui Pantelidou, Constantia Orcid: 0000-0003-2750-9352 Galbo, Phillip Orcid: 0000-0002-5391-598x Panja, Sukanya Mitrofanova, Antonina Orcid: 0000-0003-0671-6512 Wilkinson, Scott Orcid: 0000-0002-2613-8425 Whitlock, Nichelle C Trostel, Shana Y Hamid, Anis A Kibel, Adam S Barbie, David A Orcid: 0000-0002-5422-4275 Choudhury, Atish D Pomerantz, Mark M Sweeney, Christopher J Long, Henry W Orcid: 0000-0001-6849-6629 Einstein, David J Shapiro, Geoffrey I Dougan, Stephanie K Sowalsky, Adam G Orcid: 0000-0003-2760-1853 He, Housheng Hansen Freedman, Matthew L Orcid: 0000-0002-0151-1238 Balk, Steven P Orcid: 0000-0002-4546-7371 Loda, Massimo Labbé, David P Orcid: 0000-0001-8864-8765 Olson, Brian M Ellis, Leigh Orcid: 0000-0003-4739-5049 R21 CA205627/CA/NCI NIH HHS/United States Z99 CA999999/ImNIH/Intramural NIH HHS/United States ZIA BC011679/ImNIH/Intramural NIH HHS/United States Journal Article Nat Cancer. 2021 Apr;2(4):444-456. doi: 10.1038/s43018-021-00185-w. Epub 2021 Mar 22.